English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/111877
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease

AuthorsKallitsakis, M. G.; Yáñez, Matilde; Soriano, Elena ; Marco-Contelles, José ; Hadjipavlou-Litina, Dimitra; Litinas, K. E.
Issue Date2015
CitationFuture Medicinal Chemistry 7: 103-110 (2015)
AbstractAim: Due to the complex nature of Alzheimer's disease, there is a renewed search for pleiotropic agents. Results: Purine+coumarin hybrids have been synthesized and tested for the potential treatment of Alzheimer's disease. Hybrids 6, 4a-b, 14c and 14e inhibit significantly soybean lipoxygenase, whereas derivatives 14b, c and 20a present antioxidative/lipoxygenase inhibition activities. Cholinesterase (ChE) and monoamino oxidase (MAO) inhibition studies have been carried out. Hybrid 20a is the most potent ChE inhibitor, in the low micromolar range, and selective for hBuChE (IC50 = 4.65 ± 0.23 μM), whereas hybrid 14a is the most potent MAOI, in the low micromolar range, and selective for MAO-B (IC50 = 6.8 ± 0.6 μM). Conclusion: The preliminary experimental results point to two selective multitarget lead compounds 20a and 4b.
Identifiersdoi: 10.4155/fmc.14.158
issn: 1756-8919
e-issn: 1756-8927
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.